BriaCell Therapeutics Corp.
BCTX · NASDAQ
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.25 | 1.85 | 0.67 |
| FCF Yield | -1,237.89% | -27.12% | -3.05% | -1.60% |
| EV / EBITDA | 0.31 | -18.52 | -37.31 | -27.58 |
| Quality | ||||
| ROIC | -155.30% | 2,064.84% | -92.28% | -36.41% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.07 | 5.04 | 1.17 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -16.32% | -5.33% | -100.90% | -60.55% |
| Safety | ||||
| Net Debt / EBITDA | 0.39 | 0.18 | 1.04 | 1.54 |
| Interest Coverage | -735.71 | 0.00 | 0.00 | -15,627.39 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -11,142.54 | -31,693.49 | -26,710.80 | -11,168.71 |